Photoswitchable nanoparticles for in vivo cancer chemotherapy

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1073/pnas.1315336110">http://dx.doi.org/10.1073/pnas.1315336110</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>National Academy of Sciences (U.S.)</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Fri Apr 05 08:09:30 EDT 2019</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/89081">http://hdl.handle.net/1721.1/89081</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Photoswitchable nanoparticles for in vivo cancer chemotherapy

Rong Tong a,b, Homer H. Chiang a, and Daniel S. Kohane a,1

aLaboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, Division of Critical Care Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115; and bDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139

There are many obstacles to effective cancer chemotherapy, including drug penetration and accumulation in tumors and drug systemic toxicity. The penetration of therapies into tumors is limited by the dense tumor matrix and by compression of the tumor vasculature. We have developed spiropyran-based nanoparticles that shrink from 103 to 49 nm upon irradiation at 365 nm. That shrinkage enhanced tissue penetration and drug release. Irradiation of s.c. HT-1080 tumors in nude mice administered i.v. docetaxel-containing nanoparticles was more effective treatment—than free docetaxel or encapsulated docetaxel without irradiation. Irradiation alone at the tumor site also resulted in less systemic toxicity than if the nanoparticles were irradiated before injection, presumably because of less systemically distributed free drug. The enhanced efficacy of nanoparticles in irradiated tumors may have been related to the observed enhanced tumor penetration by nanoparticles and decompression of tumor blood vessels, which may also increase nanoparticle delivery into tumors.

Nanomedicine | triggered drug delivery | photoswitching

Nanoparticles (NPs) have emerged as promising means to deliver a wide range of therapeutics for cancer treatment, as they can minimize systemic toxicity, improve drug circulation times, and enhance therapeutic effectiveness (1–4). NPs have the potential to preferentially deliver drugs to tumors, using the enhanced permeation and retention (EPR) effect (5), as new tumor vessels that sprout from existing vessels (6) are often leaky, with large pores (7, 8). However, the EPR effect is often compromised by the tumor microenvironment (9–11): compressed intratumoral blood and lymphatic vessels can hinder the delivery of blood-borne therapeutic agents (12, 13), while the dense collagen-rich extracellular matrix can retard the diffusion of nanomedicines within the tumor (14, 15). In addition, the proliferation of cancer cells is more rapid than that of capillary endothelial cells and can force vessels apart, reducing the vascular diameter and density in the tumor (16, 17). This increases the distance over which nanomedicines have to diffuse from blood vessels to target cells (>100 μm) (18). (In contrast, most cells in normal tissues are within a few micrometers of a blood vessel.) If drugs cannot be efficiently delivered to all cancer cells throughout the tumor, surviving tumor cells could repopulate and become resistant to both chemotherapy and radiotherapy (19). Overcoming physiological barriers to achieve uniform penetration remains a challenge in nanomedicine (20, 21).

We have recently developed a photoswitching nanoparticulate system that uses light as the means of remotely triggering a reversible change in particle volume that affects on-demand drug release and also enhances tissue penetration (22). Here, to enhance the NPs’ performance in vivo, they have been modified so that drug release is minimal in the absence of light triggering, yet rapid upon irradiation. We have demonstrated the efficacy of such NPs in delivering docetaxel (Dtxl) both intratumorally (i.t.) and i.v. in a s.c. implanted fibrosarcoma (HT-1080 tumor) model, when triggered with UV light (365 nm). The biodistribution and intratumoral distribution, pharmacokinetics, and toxicity of the particles are examined.

Results

Light-Triggered Size Change and Dtxl Release. We have previously shown that hybrid NPs (NPHs) (SI Appendix, Fig. S1) comprising spiropyran (SP) and lipid-polyethylene glycol (PEG) undergo a reversible volume change from 150 nm to 40 nm upon phototrigerring (22). UV light (365 nm) induces hydrophobic SP to switch to zwitterionic merocyanine (MC; SI Appendix, Fig. S1A) (23), which alters the NP-H’s physical assembly properties with an accompanying decrease in volume. Because MC is less stable than SP, MC NPs generally revert to SP NPs in darkness or under visible light, with an increase in NP size. Such reversible photoswitching of SP NP-H can enable repeated dosing from a single administration, and illumination enhances tissue penetration ex vivo.

Drug release in the absence of light triggering (i.e., in the off state) was minimized by increasing the hydrophilic interaction among lipids and SP by the introduction of cholesterol, which interacts strongly with phospholipids in liposomes to reduce bilayer permeability (24). NP-Hc (NP-H with cholesterol) were obtained by sonication of 1 wt% cholesterol with SP and lipid-PEG, and had an average hydrodynamic diameter of 103.5 ± 4.1 nm and a polydispersity of 0.03 ± 0.01. After UV illumination (1 W/cm2, 35 s, ~100% conversion to MC), MC NP-Hc size decreased to 49.2 ± 3.3 nm (polydispersity of 0.05 ± 0.02, n = 5; Fig. 1A). NP-HcH with adjustable loadings of Dtxl (Dtxl/SP NP-HcH) up to 12.6 wt% and low polydispersities were readily obtained with sizes and photoswitching capabilities similar to those of NP-H (SI Appendix, Table S1).

In the absence of UV light triggering, Dtxl was released slowly from SP NP-Hc in PBS (Fig. 1B). Upon UV irradiation (10 s), NP-HcH (Dtxl wt% = 9.4%) released 16.1% of the loaded Dtxl within 1 h as determined by HPLC, whereas less than 5% was released in the same period without UV irradiation (Fig. 1B). UV light triggering (10 s) conducted every 12 h for three cycles caused repeated increases in release at each event (n = 5; Fig. 1B).

Significance

The importance of this research is in the demonstration of the effectiveness and improved safety of a nanoparticulate chemotherapy formulation that can be phototriggered to shrink in size at the tumor site. That shrinkage enhanced nanoparticle penetration into tumors and also triggered local drug release. The result was increased efficacy and reduced systemic toxicity. The phototriggered formulation also relieved the compression of tumor blood vessels, which is a recognized barrier to nanoparticle accumulation in tumors.

Author contributions: R.T. and D.S.K. designed research; R.T. and H.H.C. performed research; R.T. and D.S.K. analyzed data; and R.T. and D.S.K. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

To whom correspondence should be addressed. E-mail: daniel.kohane@childrens.harvard.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1315336110/-/DCSupplemental.
Light-triggered drug release increased the cytotoxicity of Dtxl/SP NP<sub>HC</sub> in HT-1080 cells. Cells were incubated with Dtxl/SP NP<sub>HC</sub> for 4 h, then washed and incubated in media without NP<sub>HC</sub>, irradiated (10 s), and further incubated for a total of 24 h. We have previously found that NP<sub>HC</sub> could be internalized by HeLa cells within 2 h (22). Cell viability was then measured with an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (25). Light-triggered Dtxl/SP NP<sub>HC</sub> were more cytotoxic than Dtxl/SP NP<sub>HC</sub> without light triggering (n = 6, P < 0.005; Fig. 1C), presumably due to UV-triggered rapid intracellular release of Dtxl (22). SP NP<sub>HC</sub> themselves (no drug), with or without UV irradiation (10 s), did not cause significant cytotoxicity in HT-1080 cells except at extremely high concentrations (SI Appendix, Fig. S2).

We verified that the cholesterol-modified SP NP<sub>HC</sub> retained the light-triggered enhancement of diffusion that we had reported for NP<sub>H</sub> (22) by measuring diffusion through a well-established one-dimensional collagen gel model (26) with the same collagen concentration as in the matrix of 6–8-mm-diameter HT-1080 tumors [3.72 ± 0.63 mg/g tumor (n = 5) determined by a colorimetric hydroxyproline assay]. SP NP<sub>H</sub> (1 mg/mL) containing the dye Cy5 (1 wt%) penetrated 6.7 ± 0.2 mm within 8 h at 37 °C without UV triggering; when triggered by UV for 10 s, they penetrated 10.5 ± 0.3 mm (56% further; n = 4, P < 0.005). The mechanical properties of collagen are essentially unchanged by 1 h irradiation at 254 nm UV light at 15.8 J/cm<sup>2</sup> (27).

**UV Irradiation ex Vivo.** We investigated the irradiation time required to trigger photoswitchable NP<sub>HC</sub> through the skin. The absorbance at 365 nm of mouse skin [from 6 to 8 wk nu/nu (nude) mice] was 0.758 ± 0.066 (n = 4)—that is, ~17% of light at 365 nm was transmitted (SI Appendix, Fig. S3A, black curve). Light absorption of skin above s.c. HT-1080 tumors was similar (SI Appendix, Fig. S3A, red curve). SP NP<sub>HC</sub> exhibited rapid photoswitching kinetics (half-time 14.8 s, same as described for NP<sub>H</sub>) (22); through skin, the half-time was 25.9 s at a UV intensity of 1 W/cm<sup>2</sup> (SI Appendix, Fig. S3B). The half-time of the conversion from MC NP<sub>HC</sub> to SP NP<sub>HC</sub> was 2,741 ± 27 s in vitro. This suggests that the triggered NPs would remain as MC NP<sub>HC</sub> (i.e., reduced in size) for a few hours, during which they would penetrate tumors.

**Intratumoral Injection of NP<sub>HC</sub>**. As a preliminary to studies of i.v. administered SP NP<sub>HC</sub>, we examined their intratumoral distribution and effectiveness when delivered by direct injection at the tumor site. Perfuse this entailed NP deposition at the periphery of the tumors due to the difficulty of injecting into the high pressure deep in the tumor (28). SP NP<sub>HC</sub> containing the fluorescent dye Cy5 (1 mg/kg) were injected into s.c. HT-1080 tumors (diameters ~6–8 mm), with or without immediately subsequent light triggering (15 s, 1 W/cm<sup>2</sup>). Frozen sections of tumors collected 12 h postinjection revealed that the fluorescence of Cy5/SP NP<sub>HC</sub> was restricted to the injection site in the absence of light triggering, whereas light-triggered (365 nm, 15 s) NP<sub>HC</sub> were more broadly distributed (Fig. 2A and B), as quantified by percentage of tumor area positive for Cy5 fluorescence (Fig. 2C; n = 4, P < 0.001). It is unlikely that the brief irradiation itself (15 J/cm<sup>2</sup>) altered the tumor vasculature; for UV light over 320 nm, the dose to cause erythema in mice skin is ~3,000 J/cm<sup>2</sup> (29–31). Therefore, the increased distribution of fluorescence after irradiation was likely due to enhanced diffusive movement of NP<sub>HC</sub>.

We evaluated the efficacy of Dtxl/SP NP<sub>HC</sub> in s.c. implanted HT-1080 tumors in nu/nu mice, once those tumors reached ca. 100 mm<sup>3</sup> in size. The following treatments were administered as a single intratumoral injection (n = 5): (i) PBS, (ii) PBS with irradiation (365 nm, 10 s, 1 W/cm<sup>2</sup>), (iii) Dtxl/SP NP<sub>HC</sub> (Dtxl 10 mg/kg), and (iv) Dtxl/SP NP<sub>HC</sub> with irradiation (10 s, 1 W/cm<sup>2</sup>) (Fig. 2C and D). Single intratumoral administrations of Dtxl/SP NP<sub>HC</sub> were efficacious in tumor reduction, with and without light triggering (Fig. 2D). Of note, two of five mice in the Dtxl/SP NP<sub>HC</sub> group (green line) were euthanized as their tumor size exceeded 500 mm<sup>3</sup> (tumor diameter over 1 cm) on day 18 and 29 (red arrows). Data are medians ± quartiles.

**Fig. 1.** In vitro characterization of photoswitching SP NP<sub>HC</sub>. (A) Dynamic light-scattering measurement of size changes of SP NP<sub>HC</sub> upon alternating UV (355 nm) and visible light illumination (500–600 nm, 5 min, 0.5 W/cm<sup>2</sup>). (B) Release of Dtxl from SP NP<sub>HC</sub> in the absence of irradiation; with UV irradiation for 10 s at t = 0 or with repeated UV irradiation at t = 0, 12, and 24 h. The times of irradiation are indicated by purple arrows (n = 5). (C) Effect of Dtxl/SP NP<sub>HC</sub> on HT-1080 cell viability, by MTT assay. Cells were incubated with NP<sub>HC</sub> for 4 h, washed with NP-free media, irradiated (10 s, 1 W/cm<sup>2</sup>), and further incubated for a total time of 24 h. Data are means ± SD, n = 6; asterisks indicate P < 0.005. Dtxl, docetaxel; SP, spiropyran.

**Fig. 2.** Intratumoral distribution and efficacy of i.t. injected SP NP<sub>HC</sub> in animals with s.c. HT-1080 tumors. (A and B) Cy5/SP NP<sub>HC</sub> (Cy5 dose, 1 mg/kg) were injected i.t., then the tumors were either (A) not treated or (B) irradiated for 15 s at 365 nm, and excised for immunofluorescence imaging 12 h post-irradiation. Blue, cell nuclei stained by DAPI; green, Cy5/SP NP<sub>HC</sub> (scale bar, 50 μm). (C) Quantification of the percentage of tumor area positive for Cy5 (n = 4, with four sections from four tumors). Asterisks indicate P < 0.005. (D) In vivo efficacy of Dtxl/SP NP<sub>HC</sub> (Dtxl dose: 10 mg/kg, n = 5) given i.t. to s.c. HT-1080 tumors, without or with light triggering (15 s, 1 W/cm<sup>2</sup>). Two of five mice in the Dtxl/SP NP<sub>HC</sub> group (green line) were euthanized as their tumor size exceeded 500 mm<sup>3</sup> (tumor diameter over 1 cm) on day 18 and 29 (red arrows). Data are medians ± quartiles.
NP_HC group had to be euthanized per animal protocol, as their tumor volumes exceeded 500 mm³ (~1 cm diameter) on days 18 and 29 (SI Appendix, Fig. S44). In contrast, all mice treated with Dtxl/SP NP_HC and irradiation showed significant tumor reduction. In the groups administered PBS only (without and with light triggering), the tumors in all animals grew within 2 wk to the point where euthanasia was indicated. Animals treated with Dtxl/SP NP_HC did not show appreciable changes in body weight over 15 d, suggesting no severe systemic toxicity (SI Appendix, Fig. S4B).

**Toxicity of Systemically Administered NP_HCs.** Animals were given a single i.v. bolus of SP NP_HC in nu/nu mice with 4–5-mm-diameter s.c. tumors at a high dosage of 400 mg/kg. Particles were drug free or contained Dtxl (40 mg/kg; dosage based on reported maximum [olerated dosage] (32). The tumor sites were irradiated (1 W/cm² for 20 s) or not in animals receiving SP NP_HCs containing Dtxl. Mice remained healthy during an observation period of 2 wk, without behavior changes or severe weight loss (<10%). Blood tests suggested that the hepatic function of the mice was normal (for alkaline phosphatase and alanine transferase, P > 0.1 for the comparison between mice treated with PBS and Dtxl/SP NP_HC with irradiation; SI Appendix, Fig. S5). Red blood cell counts and characteristics were also not affected by the large dose of SP NP_HC (P > 0.2 between mice treated with PBS and Dtxl/SP NP_HC with irradiation; SI Appendix, Fig. S6). White blood cell counts were also not affected (P > 0.2 between mice treated with PBS and Dtxl/SP NP_HC with irradiation) and platelet counts were not depressed (SI Appendix, Fig. S7). Hematoxylin-eosin-stained histological sections of organs harvested 72 h postinjection were normal (SI Appendix, Fig. S8).

**Photostripping Enhances Efficacy of Dtxl NP_HCs.** We evaluated the efficacy of i.v.-injected Dtxl/SP NP_HC in s.c. HT-1080 tumors (Fig. 3 A and B; SI Appendix, Table S2). After tumors reached 100–150 mm³ in volume, mice were treated with the following regimens (n = 5): (i) PBS, (ii) Dtxl, (iii) Dtxl/SP NP_HC, (iv) Dtxl/SP NP_HC converted to Dtxl/MC NP_HC by irradiation just before injection (“preirradiation”), or (v) Dtxl/SP NP_HC with irradiation (20 s, 1 W/cm²) onto the tumor site 30 min postinjection (“postirradiation”); see SI Appendix, Methods S6 for the rationales for irradiation times). The Dtxl dosing was 40 mg/kg. Mice treated with free Dtxl experienced severe weight loss (20%) within 4 d; significant body weight loss at day 6 was also seen in the group treated with Dtxl/MC NP_HC (preirradiation group, SI Appendix, Fig. S4C), presumably due to the considerable free Dtxl released from MC NP_HC upon irradiation (16.1% Dtxl was released in vitro within 1 h; Fig. 1B).

In the group treated with PBS, tumor volume rapidly exceeded 500 mm³ (ca. tumor diameter over 1 cm) with a median tumor volume doubling time of 2.98 d. In contrast, in mice dosed with Dtxl/SP NP_HC the median tumor volume doubling time increased to 7.55 d (SI Appendix, Table S2), and all tumors reached 500 mm³ (ca., tumor diameter over 1 cm) within 20 d. Irradiation of Dtxl/SP NP_HC at the tumor site (postirradiation) greatly improved efficacy: three of five mice survived over 100 d, with two mice having complete tumor resolution (comparison of survival curves for Dtxl/SP NP_HC groups with and without irradiation, by log-rank test, P = 0.004).

Triggering at the tumor site affected the efficacy and toxicity of Dtxl/SP NP_HC. The mouse body weights in the preirradiation group were lower than in postirradiated animals at day 12 (P = 0.04; SI Appendix, Fig. S4C). All animals in the preirradiation group were euthanized by day 75 due to tumor growth over 500 mm³ (vs. three survivors to 100 d in postirradiated animals). The median tumor volume on day 53 in the preirradiation group was 163.8 mm³ (two animals) versus 28.8 mm³ in postirradiated animals (three animals). However, the difference between survival curves of preirradiation and postirradiation groups was not statistically significant (P = 0.093 by log-rank test). The differences between the in vivo results in preirradiation and postirradiation groups likely reflected the fact that in the preirradiation group, more free drug was released systemically, whereas in postirradiated animals, more Dtxl was released in the tumor.

Histological studies (SI Appendix, Fig. S9) showed that 96 h postinjection live tumor cells in the light-triggered Dtxl/SP NP_HC group were significantly decreased (tumor cell density decreased...
by 51.5% compared with the group treated with PBS, \( P < 0.005 \), whereas the groups treated with the same NP\(_{\text{HCS}}\), with or without light triggering or free Dtxl, had decreases in cell density of 23.5% and 8.7%, respectively (\( P = 0.05 \) and 0.30 in comparison with the group treated with PBS, respectively).

**NP Pharmacokinetics and Biodistribution.** Because particle size has a marked impact on pharmacokinetics and biodistribution (33–36), we investigated whether light triggering at the tumor site would affect those parameters for Dtxl delivered by SP NP\(_{\text{HCS}}\). The Dtxl concentration in blood plasma over time was fitted to a two-compartmental PK model. The mean elimination half-time (\( t_{1/2} \)) of Dtxl/SP NP\(_{\text{HCS}}\) was 1.7-fold and 6.6-fold higher than those of nontriggered NP\(_{\text{HCS}}\) and free Dtxl, respectively (\( P < 0.005 \) for both).

**Tumor Penetration by Phototriggered NPs.** NP distribution within tumor tissues was investigated after injecting Cy5/SP NP\(_{\text{HCS}}\) i.v. and irradiating the tumor sites 30 min after administration (20 s, 1 W/cm\(^2\)). Tumor tissues were collected 24 h postinjection for immunofluorescent imaging of frozen sections. In the absence of irradiation, Cy5 fluorescence intensity remained largely localized to tumor vessels (demarcated by endothelial cells stained by anti-CD31), as indicated by the yellow color (colocalization of intratumoral vessels and Cy5/SP NP\(_{\text{HCS}}\)) in Fig. 4A, whereas Cy5 fluorescence was broadly distributed throughout the tumor tissue in irradiated mice (Fig. 4B). Quantitative analysis confirmed that the distribution of Cy5/SP NP\(_{\text{HCS}}\) was more diffuse throughout the tumor in irradiated animals, as seen in the increased percentage of tumor area positive for Cy5 fluorescence and the increased distance of extravasated NP\(_{\text{HCS}}\) from blood vessels (SI Appendix, Fig. S10).

**Effect of Light-Triggered Intratumoral Drug Release and Enhanced Penetration on the Tumor Vasculature.** We hypothesized that the increased tumor killing by photoswitching Dtxl/SP NP\(_{\text{HCS}}\) was due to tumor cell apoptosis and tumor vessel decompression resulting from light-triggered Dtxl release from NP\(_{\text{HCS}}\). The vascular decompression would enhance NP delivery into tumors. Studies have shown that systemic administration of taxanes (paclitaxel or Dtxl) can decompress intratumoral collapsed blood vessels and increase tumour blood flow without a change in vessels numbers (39), improving the delivery of therapeutics and improving tumor response (40).

Treatment with Dtxl/SP NP\(_{\text{HCS}}\) irradiated at the tumor site increased apoptosis (assayed by TUNEL staining) and decreased tumor cell proliferation (assayed by ki67 staining) in HT-1080 tumors 24 h after injection, compared with other treatment groups (SI Appendix, Fig. S11A). Tumor vessel density was not affected in any treatment group (SI Appendix, Fig. S11B). To assess the effect of treatments on blood vessel size, we measured vessel diameters in the periphery and interior of HT-1080 tumors (Fig. 4 C–E; SI Appendix, Fig. S12). Vascular diameters were significantly increased 24 h in the periphery of tumors treated with Dtxl/SP NP\(_{\text{HCS}}\), with or without irradiation, whereas those diameters did not change significantly in the untreated and free Dtxl groups (Fig. 4 C–E; SI Appendix, Fig. S12). Importantly, vascular diameters were increased in the tumor interiors, and vessels had open lumens, in animals treated with Dtxl/SP NP\(_{\text{HCS}}\) with UV light irradiation (Fig. 4E, SI Appendix, Fig. S12), compared with those treated with free Dtxl or nontriggered particles (Fig. 4 C and D; SI Appendix, Fig. S12). In the single animal treated with light-triggered Dtxl/SP NP\(_{\text{HCS}}\) that was examined at 96 h, most tumor blood vessels had lumens over 15 \( \mu \text{m} \) (SI Appendix, Fig. S13).

To determine whether the increased vessel caliber affected blood perfusion, we identified perfused tumor vessels by staining with i.v. injected fluorescein–lectin (45–47). We calculated the percentage of all vessels (stained by anti-CD31) that were perfused (stained by fluorescein–lectin). At 24 and 48 h post-injection, Dtxl/SP NP\(_{\text{HCS}}\) with light irradiation significantly increased the percentage of perfused blood vessels, compared with groups treated with Dtxl/SP NP\(_{\text{HCS}}\) or free Dtxl (both \( P < 0.01 \); SI Appendix, Fig. S11C). These changes in the vasculature, along with the enhanced perfusion, suggest a decrease in intratumoral pressure (15, 20, 39, 48–51). The increased fraction of perfused blood vessels due to the decompression of blood vessels was associated with enhanced intratumoral accumulation of NP\(_{\text{HCS}}\): Dtxl delivered by Dtxl/SP NP\(_{\text{HCS}}\) with irradiation led to intratumoral accumulation of 6% of the injected dose per gram.
Effects of light triggering of Dtxl/SP NP$_{HC}$ induced tumor cell death (SI Appendix, Fig. S11A) and increased intratumoral vessel diameters and tumor perfusion (Fig. 4E; SI Appendix, Fig. S11C). These effects, along with the particles’ light-triggered ability to penetrate collagen matrices, enhanced the accumulation of NP$_{HC}$ through tumor tissues (Fig. 4F) and inhibited tumor growth (Fig. 3A), as schematized in Fig. 5. UV-triggered size change and drug release both affected drug accumulation in the tumor (the %I.D./g), by different mechanisms. Irradiation-induced size change enhanced particle penetration and hence the %I.D./g (Fig. 3D), but did not affect the tissue structure itself in the absence of drug release (SI Appendix, Fig. S11B). UV-triggered drug release led to vessel decompression to a greater extent than did nontriggered drug release (Fig. 4E). This vessel decompression, which was established by 24 h at the latest (Fig. 4C–E), perhaps further facilitated the penetration of drug-containing particles (Fig. 4F).

It is possible that the portion of the effect of the triggered Dtxl/SP NP$_{HC}$ that is attributable to tumor penetration could be achieved by injecting NPs with the fixed smaller size of the posttriggered MC NP$_{HC}$. However, those particles would not provide the beneficial effect of the triggered drug release within the tumor (Fig. 4E). A possible solution that would provide both enhanced penetration and triggered release would be to create triggerable particles that are formulated at the smaller size. A potential difficulty in that approach, however, is that most triggerable particles of that (or any) size tend to be depleted or destroyed by the single triggering event. Consequently, they would not be available after triggering to penetrate deeper into tissues and/or provide sustained drug release in situ—as would be the case with the formulation presented here. Moreover, this formulation has the potential for repeated triggering (Fig. 1B), although we did not study the antitumor effects of that capability in this report.

The wavelength used for triggering is of obvious importance. The wavelength at which SP is triggered could not be readily shifted to the near-infrared range as the solvent bond in SP requires a high-energy photon to break (54), and near-infrared light is relatively low in energy (E = $h\nu$). However, the photoswitching of SP NP$_{HC}$ could potentially be triggered at depths up to centimeters by using near-infrared lasers (55) [e.g., by two-photon technology with wavelength ~720 nm (56–59)]. The use of near-infrared light would allow deeper tissue penetration, including through soft tissues, bone, and intact skull (53, 55, 60, 61). UV light could potentially also be used deep within the body by use of fiber optics and endoscopy (60–62).

The safety of the wavelength used also is important. UV light is divided into UVA (320–400 nm) and UVB (280–320 nm). UVA light has been used clinically to treat various diseases, including some skin conditions (e.g., psoriasis, vitiligo, atopic dermatitis) (63–65) and corneal collagen cross-linking (66, 67). Brief irradiation with 365 nm light at low energy is not considered a risk for skin cancer (68, 69). It bears mentioning that the treatment of cancers routinely involves forms of radiation that are potentially much more harmful (i.e., radiation oncology).

Conclusion

We have demonstrated the in vivo efficacy of photoswitchable NP$_{HC}$ in a s.c. implanted tumor model. There have been a small number of strategies to enhance tumor penetration (21, 33–36, 48, 70–75), including applying external energy (e.g., heat) to dilate vessels (76, 77), using tissue-penetration peptides (78–80), or degrading the stromal matrix by applying proteases (e.g., collagenase and relaxin) (81–84). Improved tumor penetration by nanotherapeutics can also be achieved by coadministration of agents that enhance tumor perfusion by decreasing tumor interstitial fluid pressure (e.g., by inhibitors of TGF-β) (85, 86). Light-triggering of Dtxl/SP NP$_{HC}$ increased NP diffusion through the tumor collagen matrix and induced release of Dtxl, which opened compressed intratumoral vessels by killing tumor cells. The resulting enhanced perfusion further increased the intratumoral penetration of NPs. Poor perfusion of tumor tissues is a recognized mechanical barrier to drug delivery (11, 87, 88); strategies like the one presented here may modify the tumor microenvironment to favor NPs’ tumor penetration and distribution. The use of nanoparticulate triggering systems may also minimize systemic toxicity.

ACKNOWLEDGMENTS. We thank the histology core facility at Koch Institute and Comparative Pathology Lab at the Massachusetts Institute of Technology for their technical support. The work was supported by a grant from Sanofi-Aventis and the National Institutes of Health (R01 GM073626).

6. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for their technical support. The work was supported by a grant from Sanofi-Aventis and the National Institutes of Health (R01 GM073626).
Tong et al. (2012) Synthesis and biological response of size-...
36. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance...
37. Cheng J, et al. (2007) Formulation of functionalized PLGA-PEG nanoparticles for in...
39. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating tumor...
40. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1997) Docetaxel enhances...
41. Timko BP, Dvir T, Kohane DS (2010) Remotely triggerable drug delivery systems. Adv...